FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129060478> ?p ?o ?g. }

• W2129060478 endingPage "3633" @default.
• W2129060478 startingPage "3626" @default.
• W2129060478 abstract "Purpose Neratinib is a potent irreversible pan-tyrosine kinase inhibitor with antitumor activity and acceptable tolerability in patients with human epidermal growth factor receptor 2 (HER2) –positive breast cancer. A multinational, open-label, phase I/II trial was conducted to determine the maximum-tolerated dose (MTD) of neratinib plus capecitabine in patients with solid tumors (part one) and to evaluate the safety and efficacy of neratinib plus capecitabine in patients with HER2-positive metastatic breast cancer (part two). Patients and Methods Part one was a 3 + 3 dose-escalation study in which patients with advanced solid tumors received oral neratinib once per day continuously plus capecitabine twice per day on days 1 to 14 of a 21-day cycle at predefined dose levels. In part two, patients with trastuzumab-pretreated HER2-positive metastatic breast cancer received neratinib plus capecitabine at the MTD. The primary end point in part two was objective response rate (ORR). Results In part one (n = 33), the combination of neratinib 240 mg per day plus capecitabine 1,500 mg/m 2 per day was defined as the MTD, which was further evaluated in part 2 (n = 72). The most common drug-related adverse events were diarrhea (88%) and palmar-plantar erythrodysesthesia syndrome (48%). In part two, the ORR was 64% (n = 39 of 61) in patients with no prior lapatinib exposure and 57% (n = 4 of 7) in patients previously treated with lapatinib. Median progression-free survival was 40.3 and 35.9 weeks, respectively. Conclusion Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." @default.
• W2129060478 created "2016-06-24" @default.
• W2129060478 creator A5001778881 @default.
• W2129060478 creator A5003526236 @default.
• W2129060478 creator A5008098651 @default.
• W2129060478 creator A5011012477 @default.
• W2129060478 creator A5015931437 @default.
• W2129060478 creator A5026459010 @default.
• W2129060478 creator A5033583599 @default.
• W2129060478 creator A5038024810 @default.
• W2129060478 creator A5038208006 @default.
• W2129060478 creator A5042829808 @default.
• W2129060478 creator A5045830304 @default.
• W2129060478 creator A5051629490 @default.
• W2129060478 creator A5082195410 @default.
• W2129060478 date "2014-11-10" @default.
• W2129060478 modified "2023-10-18" @default.
• W2129060478 title "Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer" @default.
• W2129060478 cites W1644299043 @default.
• W2129060478 cites W1964808503 @default.
• W2129060478 cites W1966574632 @default.
• W2129060478 cites W2012784647 @default.
• W2129060478 cites W2050156776 @default.
• W2129060478 cites W2090403447 @default.
• W2129060478 cites W2094793616 @default.
• W2129060478 cites W2105765694 @default.
• W2129060478 cites W2110444464 @default.
• W2129060478 cites W2113762115 @default.
• W2129060478 cites W2114159573 @default.
• W2129060478 cites W2114195503 @default.
• W2129060478 cites W2130900820 @default.
• W2129060478 cites W2139248078 @default.
• W2129060478 cites W2141393790 @default.
• W2129060478 cites W2143399650 @default.
• W2129060478 cites W2146384083 @default.
• W2129060478 cites W2147349643 @default.
• W2129060478 cites W2149773268 @default.
• W2129060478 cites W2149908785 @default.
• W2129060478 cites W2149952977 @default.
• W2129060478 cites W2154246971 @default.
• W2129060478 cites W2155794195 @default.
• W2129060478 cites W2159967578 @default.
• W2129060478 cites W2166199281 @default.
• W2129060478 cites W2271179689 @default.
• W2129060478 cites W2318605753 @default.
• W2129060478 doi "https://doi.org/10.1200/jco.2014.56.3809" @default.
• W2129060478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25287822" @default.
• W2129060478 hasPublicationYear "2014" @default.
• W2129060478 type Work @default.
• W2129060478 sameAs 2129060478 @default.
• W2129060478 citedByCount "112" @default.
• W2129060478 countsByYear W21290604782014 @default.
• W2129060478 countsByYear W21290604782015 @default.
• W2129060478 countsByYear W21290604782016 @default.
• W2129060478 countsByYear W21290604782017 @default.
• W2129060478 countsByYear W21290604782018 @default.
• W2129060478 countsByYear W21290604782019 @default.
• W2129060478 countsByYear W21290604782020 @default.
• W2129060478 countsByYear W21290604782021 @default.
• W2129060478 countsByYear W21290604782022 @default.
• W2129060478 countsByYear W21290604782023 @default.
• W2129060478 crossrefType "journal-article" @default.
• W2129060478 hasAuthorship W2129060478A5001778881 @default.
• W2129060478 hasAuthorship W2129060478A5003526236 @default.
• W2129060478 hasAuthorship W2129060478A5008098651 @default.
• W2129060478 hasAuthorship W2129060478A5011012477 @default.
• W2129060478 hasAuthorship W2129060478A5015931437 @default.
• W2129060478 hasAuthorship W2129060478A5026459010 @default.
• W2129060478 hasAuthorship W2129060478A5033583599 @default.
• W2129060478 hasAuthorship W2129060478A5038024810 @default.
• W2129060478 hasAuthorship W2129060478A5038208006 @default.
• W2129060478 hasAuthorship W2129060478A5042829808 @default.
• W2129060478 hasAuthorship W2129060478A5045830304 @default.
• W2129060478 hasAuthorship W2129060478A5051629490 @default.
• W2129060478 hasAuthorship W2129060478A5082195410 @default.
• W2129060478 hasConcept C121608353 @default.
• W2129060478 hasConcept C126322002 @default.
• W2129060478 hasConcept C143998085 @default.
• W2129060478 hasConcept C197934379 @default.
• W2129060478 hasConcept C2775930923 @default.
• W2129060478 hasConcept C2777329042 @default.
• W2129060478 hasConcept C2777909004 @default.
• W2129060478 hasConcept C2778375690 @default.
• W2129060478 hasConcept C2779413316 @default.
• W2129060478 hasConcept C2779786085 @default.
• W2129060478 hasConcept C2779984678 @default.
• W2129060478 hasConcept C31760486 @default.
• W2129060478 hasConcept C526805850 @default.
• W2129060478 hasConcept C530470458 @default.
• W2129060478 hasConcept C535046627 @default.
• W2129060478 hasConcept C71924100 @default.
• W2129060478 hasConceptScore W2129060478C121608353 @default.
• W2129060478 hasConceptScore W2129060478C126322002 @default.
• W2129060478 hasConceptScore W2129060478C143998085 @default.
• W2129060478 hasConceptScore W2129060478C197934379 @default.
• W2129060478 hasConceptScore W2129060478C2775930923 @default.
• W2129060478 hasConceptScore W2129060478C2777329042 @default.
• W2129060478 hasConceptScore W2129060478C2777909004 @default.

• next